Navigation Links
FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer

SUNNYVALE, Calif., July 23 /PRNewswire/ -- FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), today announced the appointment of Chris Barys to the position of Chief Operating Officer. Chris previously held the position of Executive VP, Sales and Marketing at FlowCardia and has over 18 years of experience in Medical Devices including the last 2 years at FlowCardia.

Prior to FlowCardia, Mr. Barys served as Vice President of Sales and Marketing for the Peripheral Vascular Systems business for Edwards Lifesciences where he had broad responsibility for this rapidly growing business segment. In his new role at FlowCardia, Mr. Barys will assume responsibility for R&D, Quality, Clinical and Regulatory functions in addition to Sales and Marketing. This move will consolidate all primary "customer touching" functions within the company under Mr. Barys.

"We are excited to have Chris take on this new role at FlowCardia as this is a critical time for the Company," said Wick Goodspeed, President and CEO of FlowCardia. "Since joining FlowCardia he has built a sales and marketing organization that has driven sales of the Company's flagship product, the CROSSER Catheter, to record success."

FlowCardia initiated commercial efforts in February of 2008 and the Company has quickly captured a market leadership position in the CTO recanalization device space. The novel CROSSER Catheter enables peripheral and coronary interventionalists to recanalize CTOs in the central lumen of the artery, allowing physicians to treat patients more definitively with a broader range of therapeutic options like atherectomy, angioplasty and stenting.

"There is a lot of momentum right now at FlowCardia with CROSSER adoption on the rise and a significant increase in sales activity," said Mr. Barys. "FlowCardia is in the midst of rapid growth and I look forward to working with the management team and accelerating operations to keep pace with the unmet clinical need of thousands of patients with CTO's."

About the CROSSER CTO Recanalization Catheter

The CROSSER CTO Recanalization Catheter is a minimally-invasive endovascular device that is delivered to a blockage within an artery using standard guidewire techniques. The doctor then activates the CROSSER Catheter which utilizes high-frequency, mechanical vibration to cross the blockage in the central lumen of the coronary or peripheral artery. Once the CROSSER Catheter passes through the occlusion and a guidewire is advanced distally, physicians can then perform standard atherectomy, balloon angioplasty and/or stent placement to optimize the longer term outcomes. For many patients, this minimally invasive approach to CTO recanalization can eliminate the need for a potentially traumatic bypass procedure or amputation.

About FlowCardia

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture a portfolio of endovascular CTO recanalization products. Additional information is available on the company's web site:

    PR Contact Info:
    Mark Page
    Sr. Director, Marketing
    FlowCardia, Inc.
    408-617-0352 ext.301

SOURCE FlowCardia, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions ... in five states to develop and pitch their BIG ideas to improve health and ... are competing for votes to win the title of SAP's Teen Innovator, an all-expenses ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
(Date:11/24/2015)... 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) ... Pierre Laurin , President and Chief Executive Officer of ... Piper Jaffray 27 th Annual Healthcare Conference to be ... 2015. st , at 8.50am (ET) and ... the day. The presentation will be available live via a ...
Breaking Biology Technology:
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
(Date:11/17/2015)... Paris from 17 th ... Paris from 17 th until 19 th ... leader, has invented the first combined scanner in the world ... scanning surface. Until now two different scanners were required: one ... both on the same surface. This innovation is an ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
Breaking Biology News(10 mins):